ArticleFrontiers in neurology2025
Joint effects of elevated homocysteine levels and low eGFR on post-stroke cognitive impairment.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular biomarkers of cognitive impairment and neuropsychiatric symptoms after stroke in late-life-enriched cohorts: a scoping review.Journal of translational medicine · 2026Article
- Comparative characteristics of homocysteine and uric acid in patients with Parkinson's disease-related cognitive impairment and post-stroke cognitive impairment.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The correlation between serum homocysteine levels and post-stroke cognitive impairment (PSCI) remains inconsistent. This study aimed to investigate whether serum homocysteine levels are independently associated with PSCI and to assess the effects of renal function on this relationship. Methods: A retrospective analysis was conducted in 608 patients with ischemic stroke. Homocysteine levels were obtained from inpatient medical records, and global cognitive function status 1 month after discharge was assessed using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). The relationship between homocysteine levels and PSCI was evaluated using univariate and multiple linear and logistic regression analyses. Results: The mean age of the patients was 66.6 ± 4.1 years, with 48% being female. The median homocysteine level was 13.8 μmol/L (interquartile range [IQR], 11.3-17.3 μmol/L), and 39.3% of patients had total homocysteine levels above the cutoff of 15 μmol/L. After full adjustment, a stronger positive association between homocysteine levels and PSCI was observed in patients with low estimated glomerular filtration rate (eGFR), with significant interactions between eGFR and MMSE scores ( Conclusion: These findings highlight the additive value of hyperhomocysteinemia and lower eGFR in predicting incident PSCI risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.